This is a phase 1 study to establish the safety and tolerability profile of pafuramidine maleate 100 mg BID administered orally for 14 days to healthy subjects

开始日期2007-11-01

申办/合作机构

Immtech Pharmaceuticals, Inc.

NCT00408369 / Completed临床1/2期

Prophylactic Antimalarial Activity of DB289 in Volunteers Challenged With Plasmodium Falciparum

To evaluate the prophylactic activity of orally administered DB289 against Plasmodium falciparum in non-immune healthy volunteers who are challenged by the bite of five P. falciparum-infected Anopheles stephensi mosquitoes

开始日期2006-11-01

申办/合作机构

Immtech Pharmaceuticals, Inc.

NCT00302341 / Terminated临床3期

International Randomized, Controlled Phase 3 Trial of DB289 Versus Trimethoprim-sulfamethoxazole for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP) in Patients With HIV/AIDS

The purpose of this study is to demonstrate the non-inferiority of pafuramidine maleate (DB289)versus trimethoprim-sulfamethoxazole (TMP-SMX)for the treatment of mild to moderately severe Pneumocystis pneumonia (PCP).

开始日期2006-05-01

申办/合作机构

Immtech Pharmaceuticals, Inc.

100 项与 Immtech Pharmaceuticals, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Immtech Pharmaceuticals, Inc. 相关的专利（医药）

登录后查看更多信息

项与 Immtech Pharmaceuticals, Inc. 相关的文献（医药）

2005-08-16·Circulation1区 · 医学

Native C-Reactive Protein Increases Whereas Modified C-Reactive Protein Reduces Atherosclerosis in Apolipoprotein E–Knockout Mice

1区 · 医学

Article

作者: Schwedler, Susanne B. ; Wernicke, Konstanze ; Wanner, Christoph ; Krebs, Alexander ; Galle, Jan ; Potempa, Lawrence A. ; Amann, Kerstin ; Nauck, Matthias

Background— C-reactive protein (CRP) may have proatherogenic but also vasoprotective properties. We tested the hypothesis that the configuration of CRP (pentameric, or native [nCRP], versus monomeric, or modified [mCRP]) determines these different characteristics in an in vivo model. Methods and Results— We investigated the effects of human nCRP and mCRP on the development of atherosclerosis in apolipoprotein E–knockout (ApoE −/− ) mice. Treatment with nCRP for 8 weeks (2.5 mg/kg SC weekly) resulted in a 4-fold-higher mean aortic plaque area in 14-week-old female ApoE −/− mice compared with the saline controls. In contrast, mean plaque size was decreased by ≈50% in mCRP-treated ApoE −/− mice (2.5 mg/kg SC weekly). Using immunohistochemistry, we report the natural presence of the mCRP antigen in saline controls. mCRP antigen was expressed in smooth muscle cells and extracellularly in the vicinity of the plaques to a similar level in both CRP-treated groups and saline controls. mCRP and ApoB colocalized with macrophages and were equally upregulated in all aortic plaques. Vascular cell adhesion molecule expression was increased, and CD154 and intercellular adhesion molecule showed a trend for higher expression in nCRP-treated compared with mCRP-treated mice. CD154 expression in the vessel wall and plaque size correlated significantly. mCRP-treated ApoE −/− exhibited higher serum levels of the antiinflammatory interleukin-10 compared with the other 2 groups. Conclusions— Here, we show that mCRP and nCRP have opposite effects on atherosclerosis in ApoE −/− mice. These data may explain in part the conflicting activities previously reported for CRP in models of atherogenesis.

1999-01-01·Tumor Biology

Inhibition of Mouse Mammary Adenocarcinoma (EMT6) Growth and Metastases in Mice by a Modified Form of C-Reactive Protein

Article

作者: Byron Anderson ; John J. Kresl ; Lawrence A. Potempa ; James A. Radosevich

Mice were injected in the hind limb with a mouse mammary adenocarcinoma cell line, EMT6, and tumor growth at the primary site as well as the incidence of lung metastases were measured. Groups of animals were treated with the acute-phase reactant C-reactive protein, (native-CRP), or a conformationally modified form of CRP (mCRP) made by dissociating CRP subunits under chelating, denaturing conditions. Each form of CRP was injected (intravenously) through the tail vein, encapsulated in large unilamellar lipid vesicles made by an extrusion technique (LUVETs). mCRP was also injected without the LUVET carrier. Mice not treated, or treated with LUVETs alone, exhibited both progressive tumor growth at the primary site and a high incidence of metastatic lung tumors quantified at necropsy. Treatment with native-CRP encapsulated in LUVETs had little or no effect on either tumor growth or metastases. Treatment with mCRP, however, alone or encapsulated in LUVETs, effectively slowed or stopped the progression of tumor growth, and in some mice, showed a decrease in tumor size. After cessation of mCRP injections, tumor growth resumed at a rate comparable to that measured in untreated animals. Fifty to 85% of mice treated with mCRP or mCRP in LUVETs developed necrotic lesions at the primary tumor site within 24-48 h following the initial injection of protein. Furthermore, at necropsy, only 6% of mice treated with mCRP in LUVETs and 40% of mice treated with mCRP alone showed evidence of lung metastases compared to 67-80% of animals in no-treatment, native-CRP in LUVETs and in LUVET control group animals. These results show that the prototypic acute-phase reactant, CRP, has therapeutic anticancer and antimetastatic activity only when the native pentameric subunit structure is dissociated to form the mCRP conformer.

1998-10-01·Drug metabolism and disposition: the biological fate of chemicals

Biodistribution and clearance of 125I-labeled C-reactive protein and 125I-labeled modified C-reactive protein in CD-1 mice.

Article

作者: Potempa, L A ; Schaul, K W ; Motie, M

Iodinated forms of C-reactive protein (CRP), soluble modified CRP (mCRP-sol), and suspended mCRP (mCRP-susp) were injected iv into CD-1 mice, for analysis of their pharmacokinetics (PK) and biodistribution (BD). The plasma half-life of 125I-CRP, measured as 4.7 hr, agrees closely with previous reports. The PK and BD characteristics for 125I-mCRP-sol and 125I-mCRP-susp were comparable to each other and were distinctly different from those measured for CRP. Whereas approximately 50% of 125I-CRP was recoverable from plasma 5 min after injection, only approximately 5% of 125I-mCRP was similarly recoverable. The estimated volume of distribution at steady state calculated for either form of 125I-mCRP was approximately 10-fold greater than that calculated for 125I-CRP (23. 4-27.6 and 2.4 ml, respectively). The estimated mean residence times for 125I-mCRP were approximately 2 times longer than that measured for 125I-CRP (9.5-11.5 hr, compared with 4.9 hr). At both 4- and 24-hr time points, substantial amounts of 125I-mCRP were selectively distributed in the bone marrow. At 24 hr, approximately 25% of the injected 125I-mCRP-sol and 125I-mCRP-susp was localized to the bone marrow (corresponding to 92% of injected dose/g of tissue). At this time point, only 8% (or 27%/g) of 125I-CRP was localized to the bone marrow. Overall, the data presented indicate that 1) mCRP has PK and BD characteristics distinct from those of CRP; 2) injected mCRP, although it is rapidly cleared from the general circulation, accesses large body areas and is selectively localized to the bone marrow; and 3) all forms of CRP appear to be excreted in the urine.

项与 Immtech Pharmaceuticals, Inc. 相关的新闻（医药）

2006-05-15

·BioSpace

Immtech Pharmaceuticals, Inc. To Present At Rodman & Renshaw 3rd Annual Global Healthcare Conference

VERNON HILLS, Ill., May 12 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. announced today that the Company will be presenting at the Rodman and Renshaw 3rd Annual Global Healthcare Conference to be held at Le Meridien Beach Plaza Hotel, 22, Avenue Princesse Grace, Monte Carlo, Monaco. Eric L. Sorkin, Immtech's Chairman and Chief Executive Officer, will give a corporate update on Tuesday, May 16, 2006 at 10:50 a.m. CEDT. About Immtech Pharmaceuticals Immtech Pharmaceuticals, Inc. is focused on developing and commercializing drugs to treat infectious diseases, and the Company is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new treatments for Pneumocystis pneumonia, malaria and African sleeping sickness (Trypanosomiasis), and drug development programs for tuberculosis and fungal infections. The Company has worldwide licensing and exclusive commercialization rights to a large library of well-defined compounds from which a pipeline of therapeutic products could be developed. For additional information, please go to . "Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.'s business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report on Form 10-K for the most recently ended fiscal year. Immtech Pharmaceuticals, Inc. CONTACT: F. C. Thompson, 1-877-898-8038, for Immtech Pharmaceuticals, Inc. Web site:

100 项与 Immtech Pharmaceuticals, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Immtech Pharmaceuticals, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年11月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

DAP-092	隐孢子虫病更多	终止
AQ-13	疟疾更多	终止
Recombinant modified-C reactive protein(Nextera Therapeutics)	HIV感染更多	终止
DB-290	肺孢子菌肺炎更多	终止
帕呋拉定 ( Top II )	-	终止